TC Biopharm (TCBP) announces complete response in MRD patient treated with TCB008 Jun 11, 2025 08:36AM
TC Biopharm (TCBP) Announces Transition from Nasdaq to OTC Markets Mar 21, 2025 10:47AM
TC Biopharm (TCBP) Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead Mar 18, 2025 08:04AM
TC Biopharm (TCBP) enters LoI to Acquire Commercial Stage Ophthalmic Pharmaceutical Company Mar 5, 2025 08:31AM
TC Biopharm (TCBP) Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Trial Feb 10, 2025 10:00AM


Feb 5, 2025 12:05PM TC Biopharm (TCBP) announces ADS ratio change
Jan 6, 2025 01:31PM TC Biopharm (TCBP) Continues Trading on Nasdaq
Dec 31, 2024 10:16AM TC Biopharm (TCBP) Provides Update on Acquisition Strategy and Current Targets
Dec 20, 2024 08:30AM TC Biopharm (TCBP) Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
Dec 11, 2024 07:12AM CareDx (CDNA) Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
Dec 6, 2024 06:51AM
Oct 30, 2024 08:33AM TC Biopharm (TCBP) Provides Shareholder Update and Highlights Recent Milestone Achievements
Oct 25, 2024 09:45AM TC Biopharm (TCBP) Responds to Social Media Claims
Sep 9, 2024 08:32AM TC Biopharm (TCBP) to Launch Preclinical Studies for Treatment of Monkey Pox
Sep 6, 2024 04:01PM TC Biopharm (TCBP) Intends to Launch Preclinical Studies for Treatment of Monkey Pox
Sep 3, 2024 08:37AM TC Biopharm (TCBP) Announces Dosing of 5 New Patients in ACHIEVE
Aug 28, 2024 01:50PM TC Biopharm (TCBP) Granted EU Patent Covering Use of Modified Gamma Delta Cells
Aug 15, 2024 01:01PM TC Biopharm (TCBP) Regains Nasdaq Compliance
Aug 13, 2024 04:30PM TC Biopharm (TCBP) Prices 2M Share Offering at $1/sh
Jul 31, 2024 08:02AM TC Biopharm (TCBP) to Implement ADS Ratio Change
Jun 20, 2024 04:09PM TC Biopharm (TCBP) Files for 3.5M ADSs Offering by Selling Stockholders